Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1 12Phase 1/2 8Phase 3 4Phase 2/3 3Phase EARLY_PHASE1 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 4Nivolumab 4Magnetic Resonance Spectroscopy 4Temozolomide 2Specimen Handling 2Rituximab 2Radiotherapy 2Radiosurgery 2Paclitaxel 2Neoadjuvant Therapy 2Gemcitabine 2Dexamethasone 2Cisplatin 2Carboplatin 2venetoclax 1theanine 1temsirolimus 1tafasitamab 1sugemalimab 1senicapoc 1sacituzumab govitecan 1ruxolitinib 1perampanel 1paricalcitol 1pamiparib 1olaparib 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1glofitamab 1gadobutrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Temozolomide × 30 days × Clear all
NCT04614909 2026-05-14

Study of Pamiparib in Newly Diagnosed and rGBM

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Completed
50 enrolled
CNS

Glioblastoma

NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

SynerGene Therapeutics, Inc.

Phase EARLY_PHASE1 Withdrawn
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡